The antibody to hepatitis B surface antigen (anti-HBs) seropositivity rate after 3 doses of hepatitis B virus (HBV) vaccination during infancy period is known to be higher than 90%. However, a considerable number of vaccines do not form protective anti-HBs or chronologic decrease of anti-HBs. We retrospectively collected data of HBV serologic test results in 20,738 individuals from 2000 to 2015...

INTRODUCTION Recombinant hepatitis B vaccine was introduced in 1986 and has gradually replaced the plasma-derived hepatitis B vaccine. No published data are available on the immunogenicity of hepatitis B vaccines in Nigerians. The current study aimed to evaluate protective sero-conversion rates after vaccination with Shanvac-B rDNA hepatitis B vaccine in Nigerian subjects between January and Se...

BACKGROUND The malaria vaccine candidate antigen RTS,S includes parts of the pre-erythrocytic stage circumsporozoite protein fused to the Hepatitis B surface antigen. Two Adjuvant Systems are in development for this vaccine, an oil-in water emulsion--based formulation (AS02) and a formulation based on liposomes (AS01). METHODS & PRINCIPAL FINDINGS In this Phase II, double-blind study (NCT0030...

Hepatitis B is one of the alarming diseases globally. There are about 350 million chronic carriers in the world and it is estimated that 75-100 million of them will die of liver cirrhosis and/or hepatocellular carcinoma. Treatment is expensive and cure rates are not impressive. The advent of recombinant DNA technology resulted in the development of rDNA vaccine using yeast as an expression syst...

Hepatitis B is a major disease that chronically infects millions of people in the world, especially in developing countries. Currently, one of the effective vaccines to prevent Hepatitis B is the Hepatitis B Small Antigen (HBsAg), which is mainly produced by the recombinant yeast Saccharomyces cerevisiae. In order to bring down the price, which is still too high for people in developing countri...

Hepatitis B virus (HBV) infection is a serious global health problem.The prevalence of viral hepatitis is higher in dialysis patients than in the general population because of the opportunity for exposure during the dialysis procedure. Immunization is the most effective way to prevent transmission of hepatitis B virus (HBV) and hence the development of acute or chronic hepatitis B. It is well e...

introduction and aims: in order to prevent liver cirrhosis and hepatocellular carcinoma in later life, it is essential to prevent hepatitis b virus (hbv) infection in infants. despite the availability of an effective vaccine, hepatitis b still continues to be a significant health problem. the aim of this study is to reveal the efficacy of passive and active immunoprophylaxis for preventing peri...

conclusions hbv vaccination in infancy is effective at preventing chronic hbv infection but is less effective at preventing occult hbv infection. similar studies examining the efficacy of adult hbv vaccination in preventing occult hbv have not been performed. this case highlights the importance of carefully determining the hbv status of high-risk individuals, as vaccination history and the pres...

Heprovac B is a novel recombinant vaccine. There are many vaccines available in Pakistani market but Heprovac B claims to be immunogenic even at 10 meg dose. Aim of the study is to determine whether using 10 meg of Heprovac B vaccine is safe and effective in producing sufficient immunity in Pakistani population. One hundred and twenty five subjects, who fulfilled the Inclusion criteria, were en...

BACKGROUND The development of success-oriented hepatitis-B vaccine uptake approach among dental surgeons is dependent on the availability of comprehensive baseline data. OBJECTIVE To determine the hepatitis-B vaccination status among dental surgeons in Benin City. MATERIALS AND METHODS This questionnaire-based cross-sectional study of dental surgeons in Benin City was conducted in May 2011....